SCHEMBL7201220

SCHEMBL7201220

COc1cccc(COc2ccc(S(=O)(=O)C3CCN(C(N)=O)CC3(O)C(=O)O)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 5/20 0.47
MMP13 P45452 3/20 0.47
ADAM17 P78536 1/20 0.47
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
TP53 P04637 2/20 0.43
NPC1 O15118 2/20 0.43
ALDH1A1 P00352 2/20 0.43
LMNA P02545 2/20 0.43
HTT P42858 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.41
PKM P14618 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
MAOB P27338 2/20 0.41
FFAR1 O14842 3/20 0.41
MMP2 P08253 1/20 0.40
MMP7 P09237 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7201801 0.91 MMP1 (0.57) MMP1MMP13ADAM17MAOBFFAR1
SCHEMBL7205312 0.90 MMP1 (0.47) MMP1MMP13RAB9ASMN1; SMN2NPC1
SCHEMBL7203984 0.89 MMP1 (0.45) MMP1MMP13ADAM17RAB9ANPC1
SCHEMBL7201593 0.89 MAOB (0.49) MMP1MMP13ADAM17MAOBMMP2
SCHEMBL7200563 0.89 MMP1 (0.57) MMP1MMP13ADAM17MAOBMMP2
SCHEMBL7204271 0.87 MMP1 (0.45) MMP1MMP13SMN1; SMN2ALDH1A1MMP2
SCHEMBL7205273 0.85 MMP1 (0.56) MMP1MMP13ADAM17ALDH1A1MAOB
SCHEMBL7201767 0.85 NAAA (0.44) MMP13RAB9AALDH1A1
SCHEMBL7201575 0.84 MMP13 (0.43) MMP1MMP13ADAM17MMP2
SCHEMBL7206504 0.84 MMP1 (0.47) MMP1MMP13ADAM17ALDH1A1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP1 8/4885MMP13 4/4885ADAM17 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.